IL1B and cryopyrin-associated periodic syndrome: On the basis of etiopathogenetic mechanisms rooted in overproduction of IL-1β, CAPS have been treated with anti-IL-1 agents: anakinra was the first drug utilized in these patients, with exciting results from the neurological point of view as well [97, 98].